SHMT1 and acute lymphoblastic leukemia: Interestingly, suppression of the serine hydroxymethyltransferase 1 and 2 (SHMT1-2) inhibits the progression of T-ALL in preclinical in vivo models [47], suggesting the need of improvement of different strategies -selective inhibition or epigenetic based- converging on one-carbon metabolism for the treatment of T-ALL.